Legis Daily

BIOSIM Act

USA116th CongressHR-4455| House 
| Updated: 9/23/2019
Kurt Schrader

Kurt Schrader

Democratic Representative

Oregon

Cosponsors (1)
Greg Gianforte (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Sep 20, 2019
Introduced in House
Sep 20, 2019
Referred to the Subcommittee on Health.
Sep 20, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 23, 2019
Referred to the Subcommittee on Health.
  • September 20, 2019
    Introduced in House
  • September 20, 2019
    Referred to the Subcommittee on Health.
  • September 20, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • September 23, 2019
    Referred to the Subcommittee on Health.

Health

Related Bills

  • HR 116-3: Elijah E. Cummings Lower Drug Costs Now Act
Health care costs and insuranceMedicarePrescription drugsProduct development and innovation

BIOSIM Act

USA116th CongressHR-4455| House 
| Updated: 9/23/2019
Bolstering Innovative Options to Save Immediately on Medicines Act or the BIOSIM Act This bill increases Medicare payments for biosimilars for five years. The bill applies to biosimilars for which the average sales price or wholesale acquisition cost is less than that of the reference biological product, as specified.
View Full Text

Suggested Questions

Get AI-generated questions to help you understand this bill better

Timeline
Sep 20, 2019
Introduced in House
Sep 20, 2019
Referred to the Subcommittee on Health.
Sep 20, 2019
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 23, 2019
Referred to the Subcommittee on Health.
  • September 20, 2019
    Introduced in House
  • September 20, 2019
    Referred to the Subcommittee on Health.
  • September 20, 2019
    Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
  • September 23, 2019
    Referred to the Subcommittee on Health.
Kurt Schrader

Kurt Schrader

Democratic Representative

Oregon

Cosponsors (1)
Greg Gianforte (Republican)

Ways and Means Committee, Health Subcommittee, Health Subcommittee, Energy and Commerce Committee

Health

Related Bills

  • HR 116-3: Elijah E. Cummings Lower Drug Costs Now Act
  • Introduced
  • In Committee
  • On Floor
  • Passed Chamber
  • Enacted
Health care costs and insuranceMedicarePrescription drugsProduct development and innovation